National Uptake
What is national uptake?
"National uptake" is the general implementation of any EUnetHTA output (i.e. joint assessments, submission templates, guidelines, POP Database, HTA Core Model®, etc.) in a local (national/regional) setting.
Instances of national uptake by using for example the EUnetHTA tools:
- A local HTA report produced de-novo with the use of the HTA Core Model®
- A local HTA report produced with application of the EUnetHTA Adaptation Toolkit adapting one of the national/regional reports from a different country to local settings
- A local HTA report produced as the outcome of a collaboration facilitated by the EUnetHTA POP Database
- A local HTA report produced with application of or reference to one or more of the EUnetHTA Guidelines
- A local HTA report clearly describing the development process that includes usage of or reference to any of these EUnetHTA tools
What is national adaptation?
"National adaptation" is a specific type of national uptake, i.e. the use of the EUnetHTA joint assessment results in national/regional setting. The purpose of national adaptation is to avoid duplication, to promote good practices in HTA processes and to effectively use time and financial resources.
A local HTA report can be produced by using full Core HTAs or Rapid HTAs produced in JA1 or JA2, where either the whole Core HTA/rapid HTA or parts of the Core HTA/rapid HTA is used. This can be done by:
- Summarising: The translation of a joint assessment summary used for background information in a local report
- Updating searches: The application of the original joint assessment search strategy to identify further recent evidence or extending/adding to the local search strategy
- Adapting: The systematic extraction of relevant HTA information from an existing joint assessment/Core HTA (partly or fully)
- Adopting: The use of a joint assessment without making any changes at all in its content (except a potential translation into the national language).
The minimum requirement for a national adaptation is inclusion of a explicit reference to the EUnetHTA joint assessment on which the local report was based.
The information on National Uptake and Adaptation, listed below, is based on the results from the two surveys on National Uptake conducted among all EUnetHTA Partners in April and September 2015, and on information shared by EUnetHTA Partners with the EUnetHTA Secretariat on an ongoing basis.
This list will be updated quarterly from now on. Latest update: 21 March, 2016.
The Spanish HTA Network developed the adapted national guidelines for Relative Effectiveness Assessment reports (“Guía para la elaboración de informes rápidos de evaluación de tecnologías sanitarias”), based on the EUnetHTA guidelines for REA.
| Title of EUnetHTA Output used for national adaptation | Country | Agency | Status | Link to published report | Details on adaptation process | Contact information |
| Core HTA on Abdominal aortic aneurysm (AAA) | Austria | HVB | Published 2013 | In English | In this study, a previously defined screening strategy (as proposed by EUnetHTA) was tested and evaluated. The model itself allows answering additional questions, for example "Which is the optimal screening strategy?" Such a question can be investigated considering various outcome measurements (e.g. ruptures, death cases, ICER). |
Dr. Gottfried Endel and Ingrid Wilbacher, Senior Researcher, PhD Ingrid.wilbacher@hvb.sozvers.at |
| Croatia | AAZ | Published December 2013 | In Croatian | The information from the original EUnetHTA Core HTA was adapted and the text used for the national report on the same health problem; Abdominal Aortic Aneurism. |
Mirjana Huic, MD, PhD | |
| Norway | NOKC | Published March 2014 | In English | The information from the original EUnetHTA Core HTA was adapted and transferred into the NOKC template for HTA reports. | Katrine Bjørnebek Frønsdal, Senior Researcher | |
| Core HTA on Fecal Immunochemical Test (FIT) versus guaiac-based fecal occult blood test (FOBT) for colorectal cancer screening | Austria | BIQG/GÖG and HVB | Published December 2014 | In German | The national report was produced on the EUnetHTA report. We summarized and translated essential components of Core-HTA. Furthermore we supplemented the report with national data and information and adapted it to he national setting. |
Anna Renner Ingrid Wilbacher, Senior Researcher, PhD Ingrid.wilbacher@hvb.sozvers.at |
| Austria | HVB | Published August 2015 | In German
| Data extraction of EUnetHTA Core-Assessment and of a local report published by GÖG. In addition, a systematic literature search using the EUnetHTA search strategy was performed for studies about M2-PK stool test. |
Dr. Gottfried Endel Gottfried.endel@hvb.sozves.at and Ingrid Wilbacher, Senior Researcher, PhD Ingrid.wilbacher@hvb.sovers.at | |
| Romania | NSPH MPD | Published 2015 | In Romanian with summary in English | The transferable parts of the Joint Assessment were translated in the national language and used for the local HTA report. Available national data were added to certain domains. | Silvia Gabriela Scintee Marius Ciutan | |
| Slovenia | IER and NIPH Slovenia | Published 2015 | In Slovenian | National Adaptation | Valentina Prevolnik Rupel Taja Čokl | |
| Estonia | UTA | Information missing. | Raul Kiivet | |||
| Spain | ISC III | Used in direct decision-making. | Iñaki Imaz | |||
| Spain | ISC III | Used in cross-checking evidence. | Antonio Sarrria-Santamera | |||
| Switzerland | SNHTA | Used in cross-checking evidence. | Christoph Künzli | |||
| Austria | LBI-HTA | Published 2015 | In German | The EUnetHTA assessment has been translated into German; in addition, the literature search has been updated and some recent evidence included. National data on e.g. burden of disease/cost were added whenever available. | Julia Mayer | |
| Finland | THL | Published 2015 | In Finnish | The EUnetHTA assessment was directly translated into finnish and further information on a survey conducted for ear-nose-throat-doctors was added. | Kristian Lampe | |
| Spain | AETSA | Published 2015 | In Spanish | The EUnetHTA reports was adopted, i.e. use of a joint assessment without making any changes at all in its content. | Teresa Molina Lopez | |
| Austria | HVB |
| Used in direct decision-making. | Gottfried Endel | ||
| Slovakia | MoH SK |
| Used in direct decision-making. | Tomas Tesar | ||
| Pilot rapid assessment on Biodegradable Stents for the treatment of refractory or recurrent benign oesophageal stenosis. | Austria | LBI-HTA | Published 2015 | In German | The EUnetHTA assessment was translated into German; tables were directly used from the EUnetHTA assessment. National data on e.g. burden of disease/cost were added whenever available. | Claudia Wild |
| Austria | LBI-HTA | Used in direct decision-making. | Claudia Wild | |||
| Austria | LBI-HTA | Used in cross-checking evidence. | Claudia Wild | |||
| Austria | HVB |
| Used in direct decision-making. | Gottfried Endel | ||
| The Netherlands | ZIN | Information missing. | Hedi Schelleman, Implementation Officer hschelleman@zinl.nl | |||
| Slovakia | MoH SK |
| Used in cross-checking evidence. | Tomas Tesar | ||
| Spain | AETSA |
| Used in direct decision-making. | Teresa Molina Lopez | ||
| Pilot rapid assessment on ‘Canagliflozin for the treatment of type 2 diabetes mellitus’ | ||||||
| The Netherlands | ZIN | Published March 2014 | In Dutch | The results of the indirect analyses in the EUnetHTA report were mentioned in the discussion section of the favourable effects. | Hedi Schelleman, Implementation Officer | |
| Spain | AETSA | Published July 2015 | In Spanish | The EUnetHTA assessment was adopted, i.e. systematic extraction of relevant HTA information from an existing joint assessment. | Teresa Molina Lopez | |
| Spain | MSSSI | Published June 2015 | National Adaptation | Celia Juarez Rojo | ||
| Italy | AIFA | Information missing. | Agnese Cangini | |||
| Luxembourg | CMSS |
| Used in cross-checking evidence. | Yves Bruch | ||
| Malta | MEH |
| Used in direct decision-making. | Antonia Formosa | ||
| Portugal | INFARMED |
| Used in cross-checking evidence. | João Martins | ||
| Slovakia | MoH SK |
| Used in direct decision-making. | Tomas Tesar | ||
| Spain | AETSA | Used in cross-checking evidence. | Teresa Molina Lopez | |||
| Sweden | TLV | Used in cross-checking evidence. | Johan Ponten | |||
| Pilot rapid assessment on ‘Duodenal-jejunal bypass sleeve for the treatment of obesity with or without Type II Diabetes Mellitus' | Austria | LBI-HTA and HVB | Published July 2013 | In German | An LBI report was produced alongside the EUnetHTA assessment. Due to time restrictions the LBI report had to be finished before it was possible to publish the EUnetHTA report. However, after the EUnetHTA assessment had been completed, the information provided therein was used to update the LBI report. | Dr. Ingrid Zechmeister-Koss, MA Ingrid.Zechmeister@hta.lbg.ac.at Stefan Fischer |
| The Netherlands | ZIN | Published July 2015 | In Dutch | Parts of the Joint Assessment were translated in the national language and used for the local HTA report | Hedi Schelleman, Implementation Officer | |
| Spain | ISC III | Published September 2014 | In Spanish | The National HTA report of the Duodenal-jejunal bypass sleeve updated the Joint Assessment with the new evidence availble since the publication of the Joint Assessment. | Iñaki Imaz | |
| Austria | HVB |
| Used in direct decision-making. | Gottfried Endel | ||
| Slovakia | MoH SK | Used in direct decision-making. | Tomas Tesar | |||
| Pilot rapid assessment on Ramucirumab in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma | Austria | LBI-HTA | Published September 2015 | In English | Adapting: systematic extraction of relevant HTA information from an existing joint assessment. | Anna Nachtnebel |
| Belgium | KCE | Published October 2015 | In English | Preparation of a 2 pages news-item. | Patrice Chalon | |
| Finland | FIMEA | Published 2015 | Abstract in English Report in Finnish | Adapting: systematic extraction of relevant HTA information from an existing joint assessment. | Ulla Harkonen or | |
| Belgium | RIZIV |
| Used in cross-checking evidence. | Francis Arickx | ||
| Finland | FIMEA |
| Used in cross-checking evidence. | Pertti Happonen | ||
| Slovakia | MoH SK |
| Used in direct decision-making. | Tomas Tesar | ||
| Belgium | KCE | Analysis of scientific context and its relevance, "KCE has read for you". | Patrice Chalon | |||
| Pilot rapid assessment on Renal denervation systems for treatment-resistant hypertension | Austria | HVB |
| Used in direct decision-making. | Gottfried Endel | |
| Italy | ASSR | Information missing. For further details, please contact Ingrid Wilbacher: ingrid.wilbacher@hvb.zoverz.at (WP3 LP) or Luciana Ballini luballini@regione.emilia-romagna.it | Luciana Ballini | |||
| Slovakia | MoH SK |
| Used in direct decision-making. | Tomas Tesar | ||
| Spain | AVALIA-t |
| Used in direct decision-making. | Leonor Varela | ||
| Spain | AVALIA-t |
| Used in cross-checking evidence. | Leonor Varela | ||
| Spain | IASC |
| Used in direct decision-making. | Almudena Albertos | ||
| Spain | Osteba |
| Used in cross-checking evidence. | Jose Asua | ||
| United Kingdom | HIS |
| Used in cross-checking evidence. | Jan Jones | ||
| Sorafenib for the treatment of advanced or metastatic progressive differentiated thyroid cancer | United Kingdom (Scotland) | HIS | Published July 2015 | The EUnetHTA report was referenced in discussion on impact of sorafenib on health related quality of life. | Jan Jones | |
| Belgium | RIZIV | Used in cross-checking evidence. | Francis Arickx | |||
| Portugal | INFARMED |
| Used in direct decision-making. | João Martins | ||
| Slovakia | MoH SK | Used in direct decision-making. | Tomas Tesar | |||
| Spain | IACS | Used in direct decision-making. | Almudena Albertos | |||
| Belgium | KCE | Link to summary | Analysis of scientific context and its relevance, "KCE has read for you". | Patrice Chalon | ||
| Pilot rapid assessment of Transcatheter implantable devices for mitral valve repair in adults with chronic mitral valve regurgitation | Austria | LBI-HTA | Published 2015 | In German | The EUnetHTA assessment has been translated into German; in addition, the literature search has been updated and some recent evidence included. National data on e-g- burden of disease/cost were added whenever available. | Dr. Claudia Wild |
| Austria | HVB | Used in direct decision-making. | Gottfried Endel gottfried.endel@hvb.sozvers.at | |||
| Pilot of rapid assessment on ‘Zostavax for the prevention herpes zoster' | Austria | LBI-HTA and HVB | Published November 2014 | In German | The EUnetHTA assessment was translated into German; tables were directly used from the EUnetHTA assessment. | Dr. Ingrid Zechmeister-Koss, MA |
| Austria | LBI-HTA | Published November 2014 | In German | The EUnetHTA assessment was translated into German; tables were directly used from the EUnetHTA assessment. National data on e.g. burden of disease/cost were added whenever available. |
Anna Nachtnebel | |
| The Netherlands | ZIN | Published march 2014 | In Dutch | The results of the indirect analyses in the EUnetHTA report were mentioned in the discussion section of the favourable effects. | Hedi Schelleman, Implementation Officer | |
| Austria | HVB | Used in direct decision-making. | Gottfried Endel | |||
| Belgium | RIZIV | Used in cross-checking evidence. | Francis Arickx | |||
| Sweden | TLV | Used in cross-checking evidence. | Johan Ponten | |||
Endovascular therapy using mechanical thrombectomy devices for acute ischaemic stroke | Austria | LBI-HTA | Published March 2016 | Link to report | German Summary of the correspondent EUnetHTA Report | Claudia Wild |
| France | HAS | Published February 2017 | in French | Is partially based on the JA2 EUnetHTA Joint Assessment
| Huguette Lhuillier-Nkandjeu h.lhuIlliernkandjeu@has-sante.fr | |
| Ireland | HIQA | Published February 2017 | Link to report | This report, which references EUnetHTA, represents an update and adaptation of the REA undertaken as part of JA2. |
